BMS’ Abecma Receives EC’s Approval for the Treatment of Relapsed/Refractory Multiple Myeloma
Shots:
- The EC’s approval was based on the P-III (KarMMa-3) trial assessing Abecma vs standard combination regimens for treating r/r multiple myeloma patients receiving 2-4 previous lines of therapy such as IMiD, a PI & an anti-CD38 mAb as well as refractory to last treatment regimen
- The pre-specified interim analysis at a median follow-up of 18.6mos. depicted improved PFS with an mPFS of 13.8mos. vs 4.4mos., a reduced disease progression or death risk by 51%, improved ORR in 71.3% of responders & a complete or stringent complete response in 43.7% vs 5.3% of them
- Furthermore, the study showed an mOS of 41.4mos. vs 37.9mos. The real-world evidence showed an mOS of ~13mos. in patients with triple-class exposed RRMM
Ref: BMS | Image: BMS
Related News:- BMS Receives the CHMP’s Positive Opinion for Abecma (idecabtagene vicleucel) to Treat Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
